ClinicalTrials.gg
CompletedNCT03674658Updated Sep 23, 2021

Propafenone in the Treatment of Atrial Fibrillation

An interventional study of Propafenone in Atrial Fibrillation, sponsored by TSH Biopharm Corporation Limited. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-09-23.

Sponsored by TSH Biopharm Corporation Limited · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Atrial Fibrillation with a site in Taiwan — 17 open to participants now, 25 under way, 3 of them phase 3. Atrial Fibrillation · Taiwan.

Enrollment
56th of 67
71 · median 448
Started
2019
with 3 others
No phase
34 of 95
12 open now
Registered
47th of 95
by date

Among the 95 studies in Atrial Fibrillation with a site in Taiwan, this one is the 56th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2019, is one of 34 with no phase, and was the 47th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

17 of the 95 studies in Atrial Fibrillation with a site in Taiwan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Atrial Fibrillation with a site in Taiwan, or all of them as a file.
02

Study summary

This is a open label randomized, multi-center study conducted in Taiwan. The study aims to evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.

Read the detailed description

This is a open label randomized, multi-center study conducted in Taiwan. The study aims to evaluate the effectiveness and safety of oral Rhynorm (A drug) and Rytmonorm (B drug) for the conversion of paroxysmal AF and is designed to evaluate the improvement in sinus rhythm restoration after the treatment with Rhynorm (A drug) and Rytmonorm (B drug) for 24 weeks.

This study comprised of three phases: a screening phase, a washout run-in qualifying phase lasting about 7 days, and a treatment phase of 24 weeks. A total of 60 evaluable subjects is planned to be enrolled. With an estimation of 20% dropout rate, 72 patients will be enrolled to reach 60 evaluable patients at the end of study. After screening for eligibility, the eligible subjects will be randomly assigned to either of the two gruop. The two-group are shown in the following table.

Group Treatment Drug Group A Rhynorm (A drug) Group B Rytmonorm (B drug) Patients with arrhythmia will be screened for eligibility after providing informed consent. Patients present with the symptoms of arrhythmia after withdrawn from other prohibited anti-AF agents for at least 7 days and completed run-in period event recorded will be qualified for entering this study and will be randomized to Rhynorm (A drug) treatment group or Rytmonorm (B drug) reference drud group in a 1:1 ratio.

The clinical evaluation will be recorded during the study period. Before treating with Rhynorm (A drug) and Rytmonorm (B drug), the physical examination and condition will be tracked and recorded for at least 7 days as the historical data.

During the treatment period, the subjects still had a routine OPD visit. Record symptom event and event recorder monitoring on OPD visit.

Safety assessments on all randomized subjects include adverse events, vital signs, and laboratory tests (hematology and biochemistry). Any adverse events, symptom events and concomitant medications/therapies will be recorded on the CRFs throughout the study.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are 20\~80 years of age
  2. Recurrent AF patients
  3. Patients with paroxysmal atrial fibrillation
  4. Patients diagnosed with one of the monitoring within 12 months prior screening visit:

    1. 12-lead electrocardiogram
    2. ECG used to make a 30 second one of recording
    3. 24 hours ECG (Holter Monitor)
    4. Long term ECG (Event Monitor)
  5. Patient may be receiving stable dose of propafenone since at least 4 weeks prior screening visit.
  6. Agree to and are able to follow the study procedures
  7. Understand the nature of the study, and have signed forms

Exclusion criteria

Exclusion Criteria:

  1. Permanent or persistent AF
  2. Any of the following heart disease:

    1. class III or IV angina pectoris or heart failure
    2. previous electrocardiographic evidence of second- or third-degree atrioventricular block;
    3. Sinus node disease, AV conduction disturbance or bundle branch block in the absence of an artificial pacemaker
    4. Hemodynamic moderate valvular heart disease (stenosis and/or incompetent; regurgitation)
    5. Brugada syndrome
    6. Left ventricular EF\< 50%
    7. Acute myocardial infarction or unstable angina within the previous 12 months
    8. Cardiogenic shock (excluding arrhythrmia shock) within the previous 12 months
    9. Acute pericarditis or myocarditis within the previous 6 months
    10. Cardiac or thoracic surgery within the previous 6 months
  3. Symptomatic Bradycardia (heart rate less than 50 beats per minute)
  4. Hemodynamic instability, defined as hypotension (SBP \< 90 mm Hg)
  5. Hyperthyroidism
  6. Bronchospastic disorders or severe obstructive pulmonary disease
  7. Correctable AF for other reasons
  8. Marked electrolyte imbalance
  9. Patients with abnormalities in the following laboratory parameters:

    1. or ALT ≥ 3X (ULN)
    2. Total ≥ 2X ULN
    3. Creatinine ≥ 2.5 mg/dL
    4. \< 10 g/dL
    5. \< 100,000/uL
  10. Patients with known or history of allergy to Propafenone.
  11. Female patients who are pregnant or lactating.
  12. Female patients of child-bearing potentiality who do not agree to use an effective method of during the study
  13. Patients currently participating in any drug related clinical trial within 30 days
  14. Patients with propagating factor (e.g. Alcohol Abuse induced AF)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    A drug

    Rhynorm(A drug)

    Drug: Propafenone

  • Active comparator
    B drug

    Rytmonorm (B drug)

    Drug: Propafenone

Interventions

  • oral, TID

    Also known as: A drug: Rhynorm, B drug: Rytmonorm

06

What researchers measure

Primary outcomes

  1. proportion of patients with recurrent AF

    To compare the effect of Rhynorm (A drug) and Rytmonorm (B drug) over 24 weeks of treatment based on the proportion of patients with recurrent AF

    Time frame: 24 weeks treatment

07

Study locations

1 site
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Aug 2021, 25 months.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 25 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2018
First posted
Sep 17, 2018
StartActual
Jul 11, 2019
Primary completionActual
Aug 17, 2021
CompletionActual
Aug 17, 2021
Last update
Sep 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03674658
Lead sponsor
TSH Biopharm Corporation Limited
Responsible party
Sponsor
First posted
Sep 17, 2018
Start date
Jul 11, 2019
Primary completion
Aug 17, 2021
Completion
Aug 17, 2021
Last update
Sep 23, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propafenone

Start the discussion